Treatment News : Approval of Gilead and Tibotec’s New Combo HIV Pill Hits Snag

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 26, 2011

Approval of Gilead and Tibotec’s New Combo HIV Pill Hits Snag

Gilead Sciences announced January 25 that the U.S. Food and Drug Administration (FDA) has refused to accept the company’s New Drug Application (NDA) supporting the approval of a new three-in-one HIV drug that combines Tibotec’s rilpivirine (TMC278) with Gilead’s Truvada (tenofovir plus emtricitabine).

The company expects to be in a position to resubmit the NDA by the end of March, once it is ready to provide additional information requested by the FDA. The agency is interested in the chemistry and manufacturing of the three-in-one drug, notably its methodology of establishing acceptable levels of an impurity related to emtricitabine that was found while testing the combination tablet.

Gilead’s chief scientific officer, Norbert Bischofberger, told Bloomberg news that FDA’s refusal to accept the filling will actually help ensure that the drug will still receive a priority six-month review.

“I am confident that this will result in only a minor delay in bringing this important new treatment to patients,” said John Martin, Gilead’s chief executive officer.

While Gilead is responsible for manufacturing the combination pill and getting its FDA approval, Tibotec—a subsidiary of Johnson & Johnson—remains responsible for manufacturing rilpivirine as a stand-alone drug. Gilead’s reported manufacturing problem has affected the FDA review only of the combination pill.

Search: Gilead, Tibotec, Johnson & Johnson, rilpivirine, TMC278, FDA, approval, impurity, emtricitabine, tenofovir, Truvada


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    slimcuteguy
    Asheville
    North Carolina


    pevans
    San Francisco
    California


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.